Valuation dashboard for Pluri Inc. (PLUR) with P/E N/A, P/B -0.55, EV/EBITDA -1.72 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology.
Analysis Summary
Trailing-twelve-month margins: gross margin 19.0%, operating margin -24.1%, net margin -24.2%.
At the current price of $1.14, PLUR has negative trailing earnings (P/E not meaningful) and an ROE of 203.55%. Market capitalisation stands at $12M.
Balance sheet quality for PLUR: current ratio of 0.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -0.55 |
| EV / EBITDA | -1.72 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-13.53 |
| vs Current Price | -1286.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| PLUR | Pluri Inc. | $12M | 203.6% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.14 |
| Market Cap | $12M |
| Exchange | NASDAQ |
| Country | IL |
Profitability
| Return on Equity | 203.55% |
| Return on Invested Capital | -117.79% |
| Return on Assets | -100.41% |
| Gross Margin | 19.00% |
| Operating Margin | -2412.14% |
| Net Margin | -2424.75% |
Related companies: ANTX · BOLD · IBIO · INTS · ITRM · JSPR · NXTC
Explore sector: Healthcare · Biotechnology
More sections of PLUR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks